Synthesis, antimycobacterial and antitumor activities of new (1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methyl N,N-disubstituted dithiocarbamate/O-alkyldithiocarbonate derivatives

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 23, 2006, Pages 7804-7815

  Güzel, Özlen ^a   Salman, Aydin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antimycobacterial activity; Antitumor activity; Dithiocarbamate; Dithiocarbonate; Saccharin

Indexed keywords

(1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 2 METHYLPIPERIDIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 2,6 DIMETHYLMORPHOLIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 3 METHYLPIPERIDIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 4 BENZYLPIPERIDIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 4 METHYLPIPERAZIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 4 METHYLPIPERIDIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL 4 PHENYLPIPERAZIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL N METHYL N [3 (DIBENZO[B,E]BICYCLO[2.2.2]OCTADIENYL)PROPYL]DITHIOCARBAMATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL N.N DIETHYLDITHIOCARBAMATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL O BUTYLDITHIOCARBONATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL O ETHYLDITHIOCARBONATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL O ISOBUTYLDITHIOCARBONATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL O ISOPROPYLDITHIOCARBONATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYL O PROPYLDITHIOCARBONATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYLMORPHOLIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYLPIPERIDIN 1 CARBODITHIOATE; (1,1 DIOXIDO 3 OXO 1,2 BENZISOTHIAZOL 2(3H) YL)METHYLPYRROLIDIN 1 CARBODITHIOATE; 2 (CHLOROMETHYL) 1,2 BENZISOTHIAZOL 3(2H) ON 1,1 DIOXIDE; 2 (HYDROXYMETHYL) 1,2 BENZISOTHIAZOL 3(2H) ON 1,1 DIOXIDE; DITHIOCARBAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SUBSTITUTION REACTION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CARBONATES; CARBOXYLIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OVARIAN NEOPLASMS; SACCHARIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIOCARBAMATES;

MYCOBACTERIUM TUBERCULOSIS;

EID: 33750090398     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.07.065     Document Type: Article

References (35)

1. Snider Jr. D.E., Raviglione M., and Kochi A. Global burden of tuberculosis. In: Bloom B. (Ed). Tuberculosis: Pathogenesis, Protection, and Control (1994), ASM Press, Washington, DC 3
2. WHO, 1997. Anti-Tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1997. WHO, WHO/TB/97.229.
3. Snider D.E., and Castro K.G. The global threat of drug-resistant tuberculosis. N. Engl. J. Med. 338 (1998) 1689
4. Lowe S.W., and Lin A.W. Carcinogenesis 21 (2000) 485
5. Yang L.L., Lee C.Y., and Yen K.Y. Cancer lett. 157 (2000) 65
6. Ateş O., Cesur N., Güner H., Uzun M., Kiraz M., and Kaya D. Farmaco 50 (1995) 361
7. Günay N.S., Çapan G., Ulusoy N., Ergenç N., Ötük G., and Kaya D. Farmaco 54 (1999) 826
8. Farghaly A.O., and Moharram A.M. Boll. Chim. Farmaceutico 138 (1999) 280
9. Xu L.Z., Jiao K., Zhang S.S., and Kuang S.P. Bull. Korean Chem. Soc. 23 (2002) 1699
10. Ozkirimli S., Apak T.I., Kiraz M., and Yegenoglu Y. Arch. Pharm. Res. 28 (2005) 1213
11. Schönenberger V.H., and Lippert P. Pharmazie 27 (1972) 139
12. Çapan G., Ergenç N., Büyüktimkin S., and Yuluǧ N. Sci. Pharm. 61 (1993) 243
13. Chourasia M.R., and Tyagi D. Indian J. Phy. Nat. Sci. 15 (1999) 15
14. Imamura H., Ohtake N., Jona H., Shimizu A., Moriya M., Sato H., Sugimoto Y., Ikeura C., Kiyonaga H., Nakano M., Nagano R., Abe S., Yamada K., Hashizume T., and Morishima H. Bioorg. Med. Chem. 9 (2001) 1571
15. Scozzafava A., Mastrolorenzo A., and Supuran C.T. Bioorg. Med. Chem. Lett. 10 (2000) 1887
16. Cao S.-L., Feng Y.-P., Jiang Y.-Y., Liu S.-Y., Ding G.-Y., and Li R.-T. Bioorg. Med. Chem. Lett. 15 (2005) 1915
17. Schönenberger V.H., and Adam A. Arzneim.-Forsch. (Drug Res.) 14 (1964) 1168
18. Schönenberger V.H., Adam A., and Adam D. Arzneim.-Forsch. (Drug Res.) 16 (1966) 734
19. Mehta G.R., Liu J., Constantinou A., Thomas F.C., Hawthorne M., You M., Gerhäuser C., Pezzuto M.J., Moon C.R., and Moriarty M.R. Carcinogenesis 16 (1995) 399
20. Gerhauser C., You M., Liu J., Moriarty R.M., Hawthorne M., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer Res. 57 (1997) 272
21. Tsuchima, T.; Wakamori, K. Japan. Patent 74 33,944, 1974; Chem. Abstr. 1975, 82, 139733c.
22. Uchiyama, Y.; Hashimoto,Y. Japan. Kokai. Patent 74 20,157, 1974; Chem. Abstr. 1974, 81, 25457q.
23. Pennino, C. J. U.S. 2,812,332, 1957; Chem. Abstr. 1958, 52, P6400b.
24. Soledade M., Pedras C., and Jha M. Bioorg. Med. Chem. 14 (2006) 4958
25. Katohgi M., Togo H., Yamaguchi K., and Yokoyama M. Tetrahedron 55 (1999) 14885
26. Ateş O., Kocabalkanli{dotless} A., Cesur N., and Ötük G. Farmaco 53 (1998) 541
27. Kutlu H. J. Fac. Pharm. Ist. Univ. 8 (1972) 33
28. Kleinpeter E., Stroehl D., Jovanovski G., and Soptrajanov B. J. Mol. Struct. 246 (1991) 185
29. Crew, P.; Rodriguez, J.; Jaspars, M. Organic Structure Analysis, Oxford University Pres, New York, pp 93-96.
30. Felumb R. Bull. Soc. Chim. France (1957) 890
31. Greef M., and Zard S.Z. Tetrahedron 60 (2004) 7781
32. Collins L.A., and Franzblau S.G. Antimicrob. Agents Chemother. 41 (1997) 1004
33. Alley M.C., Scudiero D.A., Monks P.A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., and Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48 (1988) 589
34. Grever M.R., Schepartz S.A., and Chabner B.A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19 6 (1992) 622
35. Boyd M.R., and Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34 (1995) 91